Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site

Oncologist

Volumn 14, Issue 12, 2009, Pages 1189-1197

  Hainsworth, John D ^a,b   Spigel, David R ^a,b   Thompson, Dana S ^b   Murphy, Patrick B ^b   Lane, Cassie M ^a   Waterhouse, David M ^c   Naot, Yuval ^d   Greco, F Anthony ^b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Oncology Hematology Care   (United States)

^d Integrated Community Oncology Network   (United States)

Author keywords

Bevacizumab; Carboplatin; Carcinoma of unknown primary; Empiric chemotherapy; Erlotinib; First line treatment; Paclitaxel

Indexed keywords

ANTIEMETIC AGENT; BEVACIZUMAB; CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; ERLOTINIB; PACLITAXEL; RANITIDINE;

ACNE; ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON PERFORATION; CONFUSION; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERSENSITIVITY REACTION; INTESTINE PERFORATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PACLITAXEL; QUINAZOLINES; SURVIVAL RATE; YOUNG ADULT;

EID: 75449086584     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0112     Document Type: Article

References (30)

1. Briasoulis E, Kalofonos H, Bafaloukos D et al. Carboplatin plus paclitaxel in unknown primary carcinoma:Aphase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000;18:3101-3107.
2. Greco FA, Burris HA 3rd, Litchy S et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: A Minnie Pearl Cancer Research Network study. J Clin Oncol 2002;20:1651-1656.
3. Greco FA, Erland JB, Morrissey LH et al. Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000;11:211-215.
4. Hainsworth JD, Erland JB, Kalman LA et al. Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin, and extendedschedule etoposide. J Clin Oncol 1997;15:2385-2393.
5. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
6. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
7. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
8. Nystrom JS, Weiner JM, Heffelfinger-Juttner J et al. Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 1977;4: 53-58.
9. Hainsworth JD, Spigel DR, Farley C et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: The Minnie Pearl Cancer Research Network. J Clin Oncol 2007;25:1747-1752.
10. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: Randomized, doubleblind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) [abstract 1005]. J Clin Oncol 2009; 27(15 suppl):42s.
11. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552.
12. Herbst RS, Prager D, Hermann R et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892-5899.
13. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 2009;373:1525-1531.
14. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360: 1408-1417.
15. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756.
16. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.
17. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
18. Culine S, Lortholary A, Voigt JJ et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: Results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003;21: 3479-3482.
19. Greco FA, Rodriguez GI, Shaffer DW et al. Carcinoma of unknown primary site: Sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: A Minnie Pearl Cancer Research Network phase II trial. The Oncologist 2004;9:644-652.
20. Pouessel D, Culine S, Becht C et al. Gemcitabine and docetaxel as frontline chemotherapy in patients with carcinoma of an unknown primary site. Cancer 2004;100:1257-1261.
21. Schneider BJ, El-Rayes B, Muler JH et al. Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. Cancer 2007;110:770-775.
22. Riedel F, Götte K, LiMet al. EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration. Int J Oncol 2002;21:11-16.
23. Ciardiello F, Caputo R, Bianco R et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-1465.
24. Viloria-Petit A, Crombet T, Jothy S et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 2001;61:5090-5101.
25. Herbst RS, O'Neill VJ, Fehrenbacher L et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25:4743-4750.
26. Herbst RS, Sandler A. Bevacizumab and erlotinib: A promising new approach to the treatment of advanced NSCLC. The Oncologist 2008;13: 1166-1176.
27. Ma XJ, Patel R, Wang X et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med 2006;130:465-473.
28. Talantov D, Baden J, Jatkoe T et al. A quantitative reverse transcriptasepolymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J Mol Diagn 2006;8:320-329.
29. Horlings HM, van Laar RK, Kerst JM et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 2008;26:4435-4441.
30. Varadhachary GR, Talantov D, RaberMNet al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 2008;26:4442-4448.